VYNE Therapeutics (VYNE) Return on Capital Employed (2018 - 2026)
VYNE Therapeutics (VYNE) posted Return on Capital Employed of 124.44% for Q1 2026, down 30.67% on a QoQ basis from 95.23% in Q2 2025, and down 3238.0% year-over-year from 3.97% in Q1 2025.
VYNE Therapeutics (VYNE) Return on Capital Employed (2018 - 2026) Analysis & Trends
VYNE Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 124.44% for Q1 2026.
- Quarterly Return on Capital Employed fell 3238.0% year-over-year to 124.44% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124.44% (down 3238.0% YoY) and the FY2025 annual result came in at 64.48%, up 19.0% from the prior year.
- Return on Capital Employed was 124.44% for Q1 2026 at VYNE Therapeutics, down from 95.23% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.06% in Q1 2024 and bottomed at 194.15% in Q3 2023.
- A 5-year average of 92.82% and a median of 93.65% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 13932 bps — and 2025, when it tumbled 5700 bps.
- VYNE Therapeutics' Return on Capital Employed stood at 99.44% in 2022, then surged by 42 bps to 57.44% in 2023, then tumbled by 34 bps to 76.92% in 2024, then slipped by 24 bps to 95.23% in 2025, then sank by 31 bps to 124.44% in 2026.
- Business Quant data shows VYNE's Return on Capital Employed at 124.44% in Q1 2026, 95.23% in Q2 2025, and 92.06% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -124.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.44% |
| Jun 30, 2025 | -95.23% |
| Mar 31, 2025 | -92.06% |
| Dec 31, 2024 | -76.92% |
| Sep 30, 2024 | -54.83% |
| Jun 30, 2024 | -39.84% |
| Mar 31, 2024 | -35.06% |
| Dec 31, 2023 | -57.44% |
| Sep 30, 2023 | -194.15% |
| Jun 30, 2023 | -141.17% |
| Mar 31, 2023 | -103.24% |
| Dec 31, 2022 | -99.44% |
| Dec 31, 2021 | -69.77% |
| Sep 30, 2021 | -60.07% |
| Jun 30, 2021 | -77.16% |
| Mar 31, 2021 | -222.62% |
| Dec 31, 2020 | -319.89% |
| Sep 30, 2020 | -278.95% |
| Jun 30, 2020 | -220.41% |
| Mar 31, 2020 | -186.55% |